CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia


Disclosures: RWJG, NWCJvdD, TM, GJO and SZ received research support from Janssen Pharmaceuticals. NWCJvdD, GJO and SZ received research support from Celgene. TM and GJO received research support from Novartis. NWCJvdD serves in advisory boards for Janssen Pharmaceuticals, Celgene, AMGEN, BMS, Novartis, Bayer and Servier; and received research support from AMGEN and BMS. TM received research support from Genmab and Onkimmune. GJO serves in advisory boards for Janssen Pharmaceuticals, Celgene, BMS, Novartis, Sunesis, Roche and Servier. SZ serves in in advisory boards for Janssen Pharmaceuticals, Celgene, Takeda, AMGEN and Sanofi; and received research support from Takeda.

Contributions: RWJG and ACMM provided conceptual design of experiments; JN, MT, RdJK and RWJR contributed to data acquisition; RdJK and RWJR performed mouse studies; HY, JddB provided scaffold material; JN, MT, RdJK, RWJR, LS, ACMM and RWJG analyzed data; PJP, GJO, SZ and NWCJvdD provided clinical samples and data; JN, MT, ACMM and RWJG wrote the manuscript; and GJO, SZ, TM and NWCJvdD contributed to manuscript editing.